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ABSTRACT
Introduction: In August 2012, the US Food and
Drug Administration (FDA) approved a new
single tablet once-a-day therapy for treatment-
naı¨ve HIV patients. The new tablet contains
emtricitabine and tenofovir disoproxil fumarate
as well as elvitegravir and cobicistat, a
pharmacokinetic enhancer which prolongs the
effect of elvitegravir. The new tablet (EVG/
COBI/FTC/TDF), known as Stribild (Gilead
Sciences, Foster City, CA, USA), is now the
only FDA-approved single-tablet, once-daily,
HIV medication that is composed of an
integrase-inhibitor-based regimen.
Methods: Stribild has been tested in two
randomized double-blind phase 3 clinical trials
with 1,408 patients who had not been
previously treated for HIV. In one trial, Stribild
was compared to the single-tablet regimen gold
standard medication known as Atripla (Gilead
Sciences, Foster City, CA, USA) that contains
efavirenz, emtricitabine and tenofovir
disoproxil fumarate (EFV/FTC/TDF). In the
second clinical trial, Stribild was compared to
another preferred treatment regimen of
ritonavir-boosted atazanavir (ATV/RTV) with
coformulated emtricitabine and tenofovir
disoproxil fumarate (FTC/TDF, marketed as
Truvada; Gilead Sciences, Foster City, CA,
USA).
Results: The outcomes of the two recently
published trials at 48 weeks indicated that
Stribild was noninferior to both of the
standard treatment regimens in controlling
viral load. In the Stribild versus Atripla trial,
305 of 348 patients (87.6%) on Stribild versus
296 of 352 patients (84.1%) on Atripla had an
HIV ribonucleic acid (RNA) concentration of
\50 copies/mL at week 48. In the Stribild versus
ATV/RTV with Truvada trial, 316 of 353 patients
(89.5%) on Stribild versus 308 of 355 patients
(86.8%) on Atripla had an HIV RNA
concentration of \50 copies/mL at 48 weeks.
Conclusion: Stribild had a favorable safety
profile in the two recently published
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randomized, double-blind, phase 3 clinical
trials. With the approval of Stribild, clinicians
now have more flexibility in prescribing single-
tablet regimens for patients.
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INTRODUCTION
Since the mid-1990s, a number of advances have
improved treatment efficacy as well as ease of
administration in HIV. The current standard of
care for treatment-naı¨ve patients is a
combination of at least three active
medications chosen from two or more different
classes of antiretroviral drugs, which can help
reduce HIV-associated morbidity and mortality,
and prevent transmission of the infection [1].
International guidelines recommend that
patients not previously treated for HIV receive
the nucleoside reverse transcriptase inhibitors
emtricitabine and tenofovir disoproxil fumarate
combined with a third medication: one of the
ritonavir-boosted protease inhibitors
(atazanavir or darunavir); the integrase
inhibitor raltegravir; or the nonnucleoside
reverse transcriptase inhibitor efavirenz [2].
Until recently, only one of these preferred
regimens was formulated into a single tablet
with efavirenz, emtricitabine and tenofovir
disoproxil fumarate (EFV/FTC/TDF), marketed
as Atripla (Gilead Sciences, Foster City, CA,
USA). Clinical trials have shown this tablet to
have high efficacy, ease of administration and
safety. The regimen has thus become widely
used and is considered a gold standard for
current practice [3–6].
However, not all patients can tolerate Atripla
since it can cause central nervous system (CNS)
side effects, rash and hyperlipidemia [5, 6]. It
also may increase the risk of teratogenicity
during pregnancy when administered during
the first trimester [7, 8]. Thus, the addition of
the newly US Food and Drug Administration
(FDA)-approved single tablet HIV therapy for
treatment-naı¨ve patients known as Stribild
(Gilead Sciences, Foster City, CA, USA) is a
welcome development.
The Stribild single-tablet regimen contains
emtricitabine and tenofovir disoproxil fumarate
plus elvitegravir and cobicistat (EVG/COBI/
FTC/TDF), a pharmacokinetic enhancer, which
prolongs the effect of elvitegravir. Known in
clinical studies prior to approval as ‘‘the Quad,’’
the new single-tablet regimen was approved by
the FDA in August 2012.
The purpose of this review is to discuss the
efficacy, safety outcomes and side effects of
Stribild as seen in two randomized double-blind
phase 3 clinical trials, particularly when
compared to Atripla and the treatment
regimen of ritonavir-boosted atazanavir (ATV/
RTV) (Norvir; AbbVie Inc., North Chicago, IL,
USA) plus emtricitabine and tenofovir
disoproxil fumarate (Truvada; Gilead
Sciences, Foster City, CA, USA) in treatment
naı¨ve HIV patients [9, 10].
The article will also provide current data on
the efficacy of Stribild and its component
medications, information on Stribild’s side
effects and perspective on which HIV patients
might benefit from this new single-tablet
regimen HIV medication.
The two randomized, double-blind phase 3
noninferiority clinical trials of Stribild, which
were the basis for the medication’s recent
approval by the FDA, studied its use in 1,408
adult patients not previously treated for HIV. In
the first clinical trial, Stribild was compared to
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Atripla over 48 weeks. The second phase 3 trial
measured outcomes with Stribild compared to
ATV/RTV and Truvada taken once daily, also
over 48 weeks [9, 10].
The results of both trials indicated that
Stribild had high efficacy in controlling viral
load and good tolerability over 48 weeks. It was
shown to be noninferior when compared to the
two different current HIV treatments and in
some cases, had a more favorable side-effect
profile [9, 10].
In the phase 3 clinical trials, Stribild
treatment resulted in fewer abnormal dreams,
less dizziness, insomnia and rash than, for
example, Atripla, but an increase in nausea
was observed. Stribild also resulted in fewer
cases of abnormal liver function than ATV/
RTV plus Truvada and had smaller median
increases in fasting cholesterol concentrations.
However, a greater increase in serum
creatinine was seen with Stribild than with
Atripla [9, 10].
Stribild is now the only FDA-approved
single-tablet regimen HIV medication that is
composed of an integrase-inhibitor-based
therapy. It is a highly effective alternative
therapy for treatment-naı¨ve HIV patients,
which provides clinicians with greater
flexibility in prescribing medications, without
sacrificing ease of use for patients.
METHODS
A MEDLINE search was performed using the
key words ‘‘elvitegravir,’’ ‘‘cobicistat,’’
‘‘emtricitabine,’’ and ‘‘tenofovir disoproxil
fumarate’’ to identify relevant articles for
inclusion in this review. Two randomized,
double-blind phase 3 trials of Stribild,
containing EVG/COBI/FTC/TDF, were
identified.
In the clinical trials, outcomes with Stribild
were compared to those with two other
recommended HIV drug regimens. In one
clinical trial, Stribild was compared to the
once-daily tablet Atripla. In the other trial,
outcomes with Stribild were compared to
those with the treatment regimen of ATV/RTV
plus Truvada taken once daily.
Two papers that studied the molecular
mechanisms of Stribild and its component
medications, such as cobicistat, were also
identified.
Dosages, Mechanism of Action
and Pharmacokinetics
Stribild is available in tablets containing 150 mg
of elvitegravir, 150 mg of cobicistat, 200 mg of
emtricitabine and 300 mg of tenofovir
disoproxil fumarate. The recommended dosage
is one tablet daily taken orally with food [11].
Studies on the pharmacokinetics and
bioavailability of Stribild indicate that the use
of cobicistat as a pharmacoenhancer results in
high elvitegravir blood concentrations similar
to those achieved with ritonavir-boosted
elvitegravir [12, 13]. In a study by German
et al. [13] in 2010, researchers also found that
Stribild produced clinical exposures to tenofovir
and emtricitabine that were equivalent to those
seen with coadministration of these single
agents, specifically emtricitabine 200 mg
capsules plus tenofovir 300 mg tablets.
In this study of 42 subjects, patients were
randomized to Stribild or ritonavir-boosted
elvitegravir plusTruvada. The results indicated
that elvitegravir systemic exposure and
maximum concentrations of this drug were
similar with Stribild than with ritonavir-
boosted elvitegravir plus emtricitabine/
tenofovir. Yet, trough concentrations of
elvitegravir were lower [13].
Comb Prod Ther (2013) 3:1–8 3
123
More importantly tenofovir systemic
exposure was similar in both treatment groups
but maximum concentrations and trough
concentrations were 30 and 24% higher with
Stribild [13]. Although findings from initial
clinical trials show that tenofovir is safe, there
are case reports and observational studies that
indicate it can be potentially nephrotoxic [14].
Stribild is now recommended only for patients
with normal renal function, and those on the
medication should have their renal function
monitored regularly [14].
Given these pharmacokinetics, the fixed
dose regimen of Stribild may be a favorable
alternative to protease inhibitor-containing
regimens associated with dyslipidemia and
gastrointestinal adverse events. Stribild may
also be a good choice for patients who are
unable or unwilling to tolerate the efavirenz-
related CNS side effects seen with Atripla or for
women of childbearing potential wishing to
avoid the use of a pregnancy category D
medication.
As with labels of many other drugs used to
treat HIV, Stribild’s label contains a boxed
warning stating that the drug can cause a
build-up of lactic acid in the blood and liver
problems. The warning also notes that hepatic
function should be monitored closely in
patients receiving the drug, and should not be
initiated in patients with estimated creatinine
clearance \70 mL/min. The drug is not
approved to treat chronic hepatitis B virus
infection. It is also not approved for those aged
\18 years [11].
Pivotal Phase 3 Clinical Trials of Stribild
Two randomized double-blind phase 3 clinical
trials have tested Stribild against other HIV
medications including the once-daily HIV
combination tablet, Atripla, now the gold
standard for initial HIV treatment, and the
regimen of ATV/RTV and taken with Truvada
[9, 10].
Results indicated that Stribild had good
efficacy outcomes as measured by viral
suppression or decline in HIV ribonucleic acid
(RNA) concentration, increase in CD4 cell
count, and virological failure. Both clinical
trials showed that Stribild had a good
tolerability profile. The numbers of adverse
events leading to drug discontinuation was
similar for Stribild when compared to Atripla
(4 vs. 5% for Stribild and Atripla, respectively).
In the study on Stribild and the regimen of
ATV/RTV plus Truvada, Stribild had a favorable
safety profile. In that study, 3.7% of patients on
Stribild discontinued treatment because of side
effects compared to 5.1% on ATV/RTV plus
Truvada [9, 10].
Efficacy Outcomes: Viral Suppression
and CD4 Cell Count
In the phase 3 clinical trial in which Stribild was
compared to Atripla, 700 HIV patients from
outpatient clinics in North America were
randomized to one of the two treatments. All
patients were adults diagnosed with HIV who
had not received previous antiretroviral
treatment and had plasma HIV RNA
concentrations of 5,000 copies/mL or higher.
Laboratory samples and clinical data were
regularly collected up to week 48.
Results of the trial indicated that 305 of 348
patients (87.6%) on Stribild versus 296 of 352
patients (84.1%) on Atripla had an HIV RNA
concentration of \50 copies/mL at week 48,
which met the criteria for noninferiority [10].
Mean increases in CD4 cell count were also
similar in both groups. However, patients on
Stribild appeared to fare better by week 48, with
an increase of 239 versus 206 cells/lL among
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Atripla patients (P = 0.009). Virological
resistance in both groups was infrequent [10].
Virological suppression in this phase 3 trial
was more rapid with Stribild than with Atripla.
Up to week 16, a greater number of patients on
Stribild than on Atripla achieved HIV RNA
concentrations \50 copies/mL, although after
that time point, response rates did not differ
between the two drugs. High early response
rates are typically seen with drugs in the
integrase strand transfer inhibitor class, the
investigators commented in their paper.
‘‘Although both CD4 cell response at week 48
and initial reduction in HIV RNA concentration
are significantly greater with treatments based
on strand-transfer integrase inhibitors
compared with those based on efavirenz, the
clinical significance of these differences is
unknown’’ [10].
Of patients who received treatment, 4%
(n = 31) met the criteria for resistance testing.
Of 14 patients tested in the Stribild group,
eight had resistance mutations. These eight
patients had nucleoside reverse transcriptase
inhibitor resistance mutations that included
Met184Val/Ile and Met184Val/Ile plus
Lys65Arg. Seven of eight also had primary
integrase resistance mutations (primarily
Glu92Gln [E92Q]).
Among the 17 patients in the Atripla group
tested for resistance mutations, eight developed
resistance to one or more components of the
drug. The most common resistance profile was
the Lys103Asn (K103N) mutation. Compared
with Stribild, fewer patients on Atripla (2 vs. 8)
had nucleoside/nucleotide reverse transcriptase
inhibitor mutations (Met184Val/Ile with or
without Lys65Arg) [10].
In a second randomized, double-blind phase
3 trial, Stribild was compared to another
preferred initial therapy for HIV: the protease
inhibitor regimen of ATV/RTV plus Truvada. All
medications were taken once daily. Patients in
both arms of the study each received four pills,
similar in appearance, that were either active or
placebo for Stribild, atazanavir, ritonavir, and
emtricitabine/tenofovir disoproxil fumarate. In
the trial, 718 randomly assigned patients from
146 sites in Australia, Europe, North America,
and Thailand were treated with either regimen.
The study population consisted of adults with
HIV who had no previous antiretroviral
treatment, and had plasma HIV RNA
concentrations C5,000 copies/. Patients in the
trial also had to have a glomerular filtration rate
(GFR) estimated to be at least 70 mL/min.
Patients with hepatitis B or C coinfection were
allowed to enroll. Five patients in the Stribild
group and seven in the ATV/RTV plus Truvada
were positive for hepatitis B, and 18 in the
Stribild arm and 10 in the ATV/RTV plus
Truvada were positive for HCV antibody [9].
Results indicated that Stribild was
noninferior to ATV/RTV plus Truvada after
48 weeks; 316 patients or 89.5% in the Stribild
arm versus 308 or 86.8% in the ATV/RTV plus
Truvada arm achieved an HIV RNA
concentration of B50 copies/mL. Patients on
Stribild reached viral suppression earlier, with
greater response rates up until week 16. After
that time point, response rates did not differ
between the two arms of the study [9].
CD4 cell counts rose to a similar extent in
both groups. After 48 weeks, the mean CD4 cell
count in the Stribild group had risen to 207
versus 211 cells/lL in the ATV/RTV plus
Truvada group. Development of resistance was
infrequent in both groups. The researchers
found that ‘viral suppression rates in both
groups (in the study) are among the highest
reported in clinical trials of first treatment of
adults with HIV infections, especially for
regimens based on a protease inhibitor with
ritonavir’ [9].
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The authors also noted [9] ‘patients in the
study had higher baseline CD4 cell counts than
in earlier clinical trials of treatment naı¨ve HIV
patients, which might possibly be the result of
new healthcare and HIV treatment guidelines.’
Adverse Events in Clinical Trials
The randomized double-blind phase 3 clinical
trials on Stribild highlighted some of its
advantages in terms of side effects, but also
cautions for its use.
In the phase 3 clinical trial that measured the
effects of Stribild versus Atripla on treatment
naı¨ve HIV patients, those receiving Stribild were
less likely to have the CNS effects of abnormal
dreams, dizziness and insomnia as well as rash.
Although most of these adverse events were
mild, some patients suffered moderate and
severe abnormal dreams and dizziness, and
these more serious side effects were less
common in the Stribild group (two patients or
1% vs. 13 patients or 4% in the Atripla group,
P = 0.007) [10].
Nausea was significantly more common
among Stribild users than among those on
Atripla. However, nausea was generally mild
and led to discontinuation in only one patient.
The percentage of those experiencing moderate
and severe nausea did not differ between the
two groups (3% in both arms) [10].
Stribild was shown to have significantly less
effect on cholesterol levels than Atripla. Median
fasting total cholesterol concentrations
increased significantly less from baseline to
week 48 in the Stribild group than in patients
taking Atripla (0.25 mmol/L vs. 0.49 mmol/L;
P\0.001). Also, increase in low-density
lipoprotein (LDL) concentrations was
significantly less in the Stribild group than in
the Atripla group (0.26 mmol/L vs. 0.44 mmol/
L; P = 0.001), and there was significantly less
reduction in high-density lipoprotein (HDL)
cholesterol with Stribild (0.13 mmol/L with
Stribild vs. 0.20 mmol/L with Atripla,
P = 0.001). Yet changes in the ratio of total to
HDL cholesterol and increases in triglyceride
levels were similar in the two treatment groups
[10].
The major caution for use of Stribild is its
effect on renal function; therefore regular
monitoring for these effects in patients on the
drug is crucial. In the phase 3 trial of Stribild
versus Atripla for initial HIV treatment, five
patients in the Stribild arm had renal adverse
events that led to discontinuation, including
two patients with increased serum creatinine,
two with renal failure and one with Fanconi
syndrome—all in the Stribild arm. However, the
serum creatinine of one of these patients
normalized within 2 weeks after stopping the
drug [10].
The other four patients who suffered renal
adverse events that led to discontinuation also
developed signs of tubular toxicity (with a
combination of glycosuria, proteinuria or
hypophosphatemia). All these patients had
signs of renal impairment before starting the
study. Two had proteinuria. Two had a GFR
\70 mL/min at baseline, but were allowed to
participate in the study because the eGFR
(estimated GFR) at their earlier screening visit
was [70 mL/min [10].
In the clinical trial, which assessed outcomes
with Stribild versus those with ATV/RTV plus
Truvada, discontinuation from either study
drug was infrequent. Renal adverse events
were also infrequent and only one patient in
each treatment group discontinued their
medication because of renal side effects. These
side effects, which included increased
creatinine concentration and toxic
nephropathy, reversed after discontinuation of
the study drugs [9].
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Those on Stribild were also less likely to have
increased alanine aminotransferase concen-
trations (54 patients or 15.3% vs. 76 patients or
21.6% in the ATV/RTV plus Truvada group) [9].
Those with clinically significant liver
function test abnormalities at week 48
generally had underlying hepatic disease such
as chronic hepatitis or a history of alcoholism,
according to the researchers [9].
In a commentary that accompanied
publication of the two trials, it was noted that
the two published phase 3 trials on Stribild
show that it has high efficacy as well as a good
tolerability profile. However, they noted that
Stribild’s limitations include the potential for
drug interactions and the need to be taken with
food [14].
Stribild in Clinical Practice
An advantage of Stribild is the fact that it is a
category B (unlike Atripla, which is a category
D) medication in pregnancy and can potentially
be prescribed to women of childbearing age.
When compared to other single-tablet regimen
treatments for initial HIV therapy, Stribild has
another advantage in that it can be prescribed
for patients with high viral load. This is in
contrast to the FDA label for Complera (Gilead
Sciences, Foster City, CA, USA), which contains
emtricitabine/rilpivirine/tenofovir disoproxil
fumarate, and is not recommended for people
with a viral load of [100,000.
Stribild can be particularly useful in women of
childbearing age with a viral load of over 100,000,
who express a preference for a single-tablet
regimen therapy. Other considerations when
prescribing Stribild are the patient’s renal
function. A personal and family history of
hyperlipidemia and personal or family history of
heart disease would make Stribild the drug of
choice over Atripla because of its benefits in terms
of lipid profile. However, Stribild would not be
drug of choice where there is evidence of any
hepatic disease or compromised renal function.
CONCLUSION
With 27 antiretroviral drugs now approved in
the United States, including Stribild, HIV
treatment can now be individualized to each
patient. There has also been a great deal of
progress in reducing the pill burden of
combination regimens for HIV patients, which
has increased adherence. Adherence and high
efficacy are now important cornerstones for HIV
treatment and prevention of new cases.
The addition of Stribild to HIV treatment
options for newly diagnosed patients provides us
with an important choice. It is a Category B
pregnancy drug, providing a choice for women of
childbearing age. It is also gentler on cholesterol
than other combination single-tablet regimens
for HIV. It has the advantage of being approved
without special considerations for those with a
viral load of over 100,000.
The success of Atripla, Complera and Stribild
will no doubt inspire the generation of more
single-tablet regimens for HIV—a scenario that
will be welcomed by both clinicians and
patients. When even more single-tablet
regimens become available, clinicians will have
a greater number of efficacious and convenient
treatment options for their patients. As well as
providing a range of choices for patients in terms
of their side-effect profile, these therapies can be
easily incorporated into a modern lifestyle.
Stribild offers comparable efficacy to two US
Department of Health and Human Services
Guideline preferred regimens, Atripla and ATV/
RTV with Truvada, with fewer CNS side effects
and better cholesterol changes than Atripla. It
also causes less bilirubin and triglyceride
Comb Prod Ther (2013) 3:1–8 7
123
changes than the boosted atazanavir regimens.
For childbearing women or for those who cannot
tolerate the CNS effects of Atripla, Stribild is an
especially advantageous choice.
ACKNOWLEDGMENTS
Dr. Cynthia Brinson is the guarantor for this
article, and takes responsibility for the work as a
whole.
Conflict of interest. Cynthia Brinson is on
the Speaker’s Bureau for Gilead Sciences.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. US Department of Health and Human Services
Panel on Antiretroviral Guidelines for Adults and
Adolescents. Guidelines for the use of antiretroviral
agents in HIV-1 infected adult and adolescents.
2012; Department of Health and Human Services.
http://aidsinfo.nih.gov/contentfiles/lvguidelines/
adultandadolescentgl.pdf. Accessed February 14
2013.
2. Thompson MA, Aberg JA, Cahn P, et al.
Antiretroviral treatment of adults with HIV
infection. Recommendations of the International
AIDS Society-USA Panel. JAMA. 2010;2010(304):
321–33.
3. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir
disoproxil fumarate, emtricitabine, and efavirenz
compared with zidovudine/lamivudine and
efavirenz in treatment-naive patients; 144-week
analysis. J Acquir Immune Defic Syndr. 2008;47:
74–8.
4. Sax PE, Tierney C, Collier AC, et al. Abacavir-
lamivudine versus tenofovir-emtricitabine for
initial HIV therapy. N Engl J Med. 2009;361:
2230–40.
5. Cohen CJ, Andrade-Villanueva J, Clotet B, et al.
Rilpivirine versus efavirenz with two background
nucleoside or nucleotide reverse transcriptase
inhibitors in treatment-naı¨ve adults infected with
HIV-1 (THRIVE): a phase 3 randomised,
noninferiority trial. Lancet. 2011;378:229–37.
6. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine
versus efavirenz with tenofovir and emtricitabine in
treatment-naı¨ve adults infected with HIV-1
(ECHO): a phase 3 randomised double-blind
active-controlled trail. Lancet. 2011;378:238–46.
7. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and
efficacy of raltegravir-based versus efavirenz-based
combination therapy in treatment-naive patients
with HIV-1 infection: a multicentre, double-blind
randomised controlled trail. Lancet. 2009;374:
796–806.
8. ATRIPLA (efavirenz/emtricitabine/tenofovir
disoproxil fumarate) [U.S. prescribing
information]. Foster City: Gilead Sciences and
Bristol-Myers Squibb; 2012.
9. DeJesus E, Rockstroh JK, Henry K, et al. Co-
formulated elvitegravir, cobicistat, emtricitabine,
and tenofovir disoproxil fumarate versus ritonavir-
boosted atazanavir plus co-formulated
emtricitabine and tenofovir disoproxil fumarate
for initial treatment of HIV-1 infection: a
randomised, double-blind, phase 3, non-inferiority
trial. Lancet. 2012;379:2429–38.
10. Sax PE, DeJesus E, Mills A, et al. Co-formulated
elvitegravir, cobicistat, emtricitabine, and tenofovir
versus co-formulated efavirenz, emtricitabine, and
tenofovir versus co-formulated efavirenz,
emtricitabine, and tenofovir for initial treatment
of HIV-1 infection: a randomised, double-blind,
phase 3 trial, analysis or results after 48 weeks.
Lancet. 2012;379:2439–48.
11. STRIBILD (elvitegravir, cobicistat, emtricitabine,
tenofovir disoproxil fumarate) [FDA package
insert]. Foster City: Gilead Sciences Inc.; 2012.
12. El Lepist, Phan TK, Roy A, et al. Cobicistat boosts
the intestinal absorption of transport substrates,
including HIV protease inhibitors and GS-7340,
in vitro. Antimicrob Agents Chemother.
2012;56:5409–13.
13. German P, Warren D, West S, Hui J, Kearney BP.
Pharmacokinetics and bioavailability of an
integrase and novel pharmacoenhancer-
containing single-tablet fixed-dose combination
regimen for the treatment of HIV. J Acquir
Immune Defic Syndr. 2010;55:323–9.
14. Schrijvers R, Deyser Z. Quad’s in it for antiretroviral
therapy? Lancet. 2012;379:2403–4.
8 Comb Prod Ther (2013) 3:1–8
123
